

JNK-2 Gene Silencing Lipid Nanoparticles for Elastic Matrix Regenerative Repair in **Abdominal Aortic Aneurysms (AAAs)**

Shataakshi Dahal, PhD and Anand Ramamurthi, PhD

Department of Bioengineering, Lehigh University, Bethlehem, PA



□ AAAs : dilation of abdominal aorta due to loss of elasticity

□ Primarily caused by upregulation of MMPs which breaks r matrix protein called extracellular elastin



Common approaches : pharmacologic inhibition and gene silencing

□ Pharmacologic inhibition : e.g. DOX; inhibition at protein level; is temporary and can have severe side effects


Gene silencing using siRNA : silences target mRNA and protein expression ; applicable for targeting undruggable protein

□ MAPK signaling pathways are critical regulator of MMPs

□ Major MAPKs are JNK, ERK 1/2 , ERK 5 and P38

□ JNK is primarily involved in AAAs

JNK has shown to □ Silencing of upregulate elastin and LOX expression and downregulate MMPs expression leading to AAA stabilization






Figure 2. Free siRNA delivery vs delivery using carrier¹

use lipid U We propose to nanoparticles (LNPs) as carrier for targeted delivery of JNK silencing siRNA




Figure 3. Lipid nanoparticle structure²

LNPs : Mechanism and Methods

Key outcomes and Conclusion

LNPs advantages : excellent biocompatibility and biodegradability; low toxicity and immunity; structural flexibility; ease of large scale preparation

Composition: cationic lipid DOTAP; cholesterol domain; fusogenic lipid DOPE; DSPE-PEG2000 for escaping RES





Figure 4. Lipid composition and mechanism of internalization³

Figure 5. Hydration of lipid film method⁴




□ Anionic siRNA interacts with cationic DOTAP; DOPE helps for cellular internalization by fusing with cell membrane

Lipid film hydration method for preparation of LNPs ; DOTAP : DOPE : Cholesterol = 0.5 : 0.5 : 0.5 molar ratio to a final concentration of 5.6 mM ; PEG from 0 to 40 mol% of DOTAP

□ siRNA used at N/P ratio 2.5; Encapsulation assessed my gel retardation assay

References:

- Sevilla et.al, *Molecules* **2019**, *24*(14), 2570
- 2. <u>https://en.wikipedia.org/wiki/Liposome</u>
- Hosseini ES et.al, Int J Nanomedicine **2019**; 14:4353-4366 3.
- 4. https://www.sigmaaldrich.com/US/en/technical-documents/protocol/cell-culture-and-cell-cultureanalysis/transfection-and-gene-editing/liposome-preparation



Overall, the preliminary data shows that size, charge and PDI of LNPs decreases with increase in PEG percentage. siRNA encapsulation was verified using gel retardation assay however, the size and charge of LNPs seem to increase with siRNA encapsulation which requires further validation. LNPs can thus be a potential siRNA carrier for targeted delivery to aneurysm. Future work will surface modify the LNPs for targeted delivery.